SAHA (suberoylanilide hydroxamic acid or vorinostat) is the first nonselective histone deacetylase (HDAC) inhibitor approved by the US Food and Drug Administration (FDA). SAHA affects histone acetylation in chromatin and a variety of nonhistone substrates, thus influencing many cellular processes. In particularly, SAHA induces selective apoptosis of tumor cells, although the mechanism is not well understood. A series of microarray experiments was recently conducted to investigate tumor cell-selective proapoptotic transcriptional responses induced by SAHA. Based on that gene expression time series, we propose a novel framework for detailed analysis of the mechanism of tumor cell apoptosis selectively induced by SAHA. Our analyses indicated that SAHA selectively disrupted the DNA damage response, cell cycle, p53 expression, and mitochondrial integrity of tumor samples to induce selective tumor cell apoptosis. Our results suggest a possible regulation network. Our research extends the existing research.
[1]NE Normal Univ, Natl Engn Lab Druggable Gene & Prot Screening, Changchun 130024, Peoples R China.
[2]NE Normal Univ, Sch Comp Sci & Informat Technol, Changchun 130117, Peoples R China.
[3]Jilin Univ, Hosp 1, Dept Gen Internal Med, Changchun 130021, Peoples R China.
[4]NE Normal Univ, Minist Educ, Res Ctr Agr & Med Gene Engn, Changchun 130024, Peoples R China.
(8.0+极速模式)